Navigation Links
ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
Date:8/7/2008

IRVINE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported financial results for the three months ended June 30, 2008. ISTA reported net revenue of $17.8 million for the quarter ended June 30, 2008, a 31% increase over the same quarter of 2007. The net loss for the second quarter ended June 30, 2008, was $8.5 million (or $0.26 per share), as compared with a net loss of $8.7 million (or $0.32 per share) for the same period in 2007.

"Xibrom sales continued to grow strongly during the second quarter. As our commercial business grows, ISTA's presence in the ophthalmic community is further enhanced and physicians are excited about the products we plan to bring to them in the coming years," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "With regard to our R&D pipeline, we have made solid progress over the past few months and have a number of upcoming catalysts. We expect to file the Bepreve NDA in the second half of this year, as we've successfully completed the human ocular safety studies. We also recently completed enrollment of two Phase III studies which will support an early 2009 sNDA filing for Xibrom 0.09% as a once-daily treatment for pain and inflammation associated with cataract surgery. In addition, we are working towards completing the additional T- Pred work required by the FDA for the testing of tobramycin and the pK study on the prednisolone component of the formulation. We expect to complete these additional T-Pred studies late this year or early 2009. Finally, we expect to announce in the second half of 2008 top-line data results from our additional ecabet sodium Phase II study that we initiated earlier this year."

'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 PrimeSource ... construction materials, selected SoundConnect to support ... cloud based audio and web conferencing platform GlobalMeet ... support PrimeSource’s employees’ needs. SoundConnect delivers award ... , PrimeSource Building Products will be utilizing ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... August 27, 2014 Green & Grow ... Series B funding and secured Otter Capital as a ... will accelerate commercialization of GGI’s Agriplier™ technology, building on ... , “Since our first meeting, we have been ... biological product space,” said Alan Sobba, President and CEO ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... Extension until February 3, 2009 to meet continued listing ... VSCP ) today announced that the Nasdaq Hearings ... the Nasdaq Capital Market and has,allowed the Company until ... price. The Panel,s decision represents the full extent of ...
... Inc., a,privately held biopharmaceutical company, announced today that ... executive vice president and chief,financial officer., "Bob ... 28 years of,financial management experience to Horizon, including ... private companies," said Timothy P.,Walbert, president and chief ...
... have used a wide variety of materials to build ... business, nanotechnology researchers can often be limited by the ... State University researcher Hao Yan has avoided these pitfalls ... nanostructures inside a living cell. , The results ...
Cached Biology Technology:Nasdaq Grants VirtualScopics' Request for Continued Listing 2Nasdaq Grants VirtualScopics' Request for Continued Listing 3Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer 2Using living cells as nanotechnology factories 2Using living cells as nanotechnology factories 3
(Date:8/27/2014)... is related to ability that we already possess. For ... more easily than learning how to hit a tennis ... Neural Basis of Cognition (CNBC)a joint program between the ... fundamental constraint in the brain that may explain why ... Aug. 28, 2014, issue of Nature , they ...
(Date:8/27/2014)... risk to Europe based upon a proxy for impact ... a ,big data, approach to scientific research. , The ... Health ranked the top 100 pathogens affecting humans and ... which, they believe, will help governments across the continent ... diseases, including as a result of climate change, and ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... graduate student at the Icahn School of Medicine at Mount ... "30 Under 30" list in "Science and Health." The ... transforming for the better, opening up to revolutionary new ideas ... . Ms. Shapiro, 25, a native of Rochester, New ...
... study in this month,s edition of the Journal of ... for melanoma, the most dangerous form of skin cancer. MicroRNA ... and which stay silent. Melanoma tends to lack microRNA-26a, which ... negative," says Yiqun Shellman, PhD, investigator at the CU Cancer ...
... of androgen deprivation therapies to prevent precancerous prostate abnormalities ... in men with precancers with specific genetic alterations, according ... Cancer Discovery , a journal of the American ... survival of prostate cancer cells are very dependent on ...
Cached Biology News:Mount Sinai grad student, 25, named to Forbes '30 Under 30' in Science and Healthcare 2Serendipity points to new potential target and therapy for melanoma 2Preventing prostate cancer through androgen deprivation may have harmful effects 2
...
... Digital Sight DS-U2 camera controller is the successor ... designed to interface any of the cameras in ... computer through a USB2.0 interface. The DS-U2 transmits ... cumbersome installation by equipping both hub and mass ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
...
Biology Products: